Zhu Hui-Li, Yu Rui-Min, Huang Xin-Zhi, Huang Wei
Department of Emergency Medicine, First Affiliated Hospital of Ji'nan University, Guangzhou 510630, China.
Nan Fang Yi Ke Da Xue Xue Bao. 2008 Jun;28(6):1050-1.
To study the effect of rosiglitazone on serum high-sensitivity C-reactive protein (hs-CRP), interleukin-1beta (IL-1beta), IL-6, tumor necrosis factor-alpha (TNF-alpha) and insulin resistance in obese patients with newly diagnosed type 2 diabetes.
This study involved 118 patients with newly diagnosed type 2 diabetes and obesity, who were randomly assigned into two groups for a 12-week treatment with rosiglitazone (4 mg/day, group A) or sulfonylureas (group B). Serum hs-CRP, IL-1beta, IL-6, TNF-alpha, fasting plasma glucose (FPG) and fasting insulin (FINS) were measured before and after the treatment. Insulin resistance index was calculated according to the HOMA Model.
In group A, rosiglitazone treatment resulted in significantly reduced serum hs-CRP, IL-1beta, IL-6, TNF-alpha, FPG and insulin resistance index (P<0.01). No difference in FPG was found between the two groups after the treatment (P>0.05), but serum hs-CRP, IL-1beta, IL-6, TNF-alpha and insulin resistance index were significantly lower in group A than in group B (P<0.05).
Rosiglitazone can decrease FPG, reduce the inflammation reaction and improve insulin resistance in obese patients with type 2 diabetes.
研究罗格列酮对新诊断的2型糖尿病肥胖患者血清高敏C反应蛋白（hs-CRP）、白细胞介素-1β（IL-1β）、IL-6、肿瘤坏死因子-α（TNF-α）及胰岛素抵抗的影响。
本研究纳入118例新诊断的2型糖尿病肥胖患者，随机分为两组，分别接受罗格列酮（4mg/天，A组）或磺脲类药物（B组）治疗12周。治疗前后检测血清hs-CRP、IL-1β、IL-6、TNF-α、空腹血糖（FPG）和空腹胰岛素（FINS）。根据HOMA模型计算胰岛素抵抗指数。
A组罗格列酮治疗后血清hs-CRP、IL-1β、IL-6、TNF-α、FPG及胰岛素抵抗指数显著降低（P<0.01）。治疗后两组FPG无差异（P>0.05），但A组血清hs-CRP、IL-1β、IL-6、TNF-α及胰岛素抵抗指数显著低于B组（P<0.05）。
罗格列酮可降低2型糖尿病肥胖患者的FPG，减轻炎症反应，改善胰岛素抵抗。
